Navigating Weight Loss: Can Anyone Take Wegovy?

Last reviewed: July 6, 2026

Last updated: July 6, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Semaglutide belongs to a class of medications called GLP-1 receptor agonists, originally developed to treat type 2 diabetes before its weight loss benefits became evident in clinical trials. The question of who can safely take semaglutide is not one-size-fits-all—it depends on medical history, current health status, and individual risk factors that a qualified provider must evaluate.

BMI and Weight Loss Criteria for Semaglutide Eligibility

The FDA-approved branded version carries specific weight and BMI thresholds: a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related health condition like hypertension or sleep apnea. However, clinical judgment often extends eligibility to patients with lower BMIs who carry significant metabolic dysfunction or struggle with appetite regulation driven by genetic factors. PlexusDx providers conduct individualized assessments rather than applying rigid cutoff rules, recognizing that two patients with identical BMIs may have vastly different biological drivers of weight gain.

Age also plays a role in candidacy. Semaglutide is not approved for anyone under 18 years old, though research in adolescents continues. Older adults (65+) may qualify if they have no contraindications, though dose initiation often begins more conservatively. Pregnancy and breastfeeding are absolute contraindications; the medication carries teratogenic risk in the first and second trimesters, and it is unknown whether semaglutide transfers into breast milk or harms nursing infants.

Medical Conditions That May Prevent Semaglutide Use

A personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2) is a hard stop for semaglutide therapy. Animal studies showed dose-dependent thyroid C-cell tumors, and although human evidence remains limited, the FDA warnings reflect a precautionary principle that cannot be bypassed. Patients with uncontrolled type 1 diabetes or diabetic ketoacidosis history should not begin semaglutide without specialized endocrinology input, as the medication's mechanism differs fundamentally from insulin.

Severe kidney disease (eGFR below 15 mL/min/1.73m²) requires careful consideration, though mild-to-moderate kidney disease does not automatically disqualify candidates. A history of acute pancreatitis or current chronic pancreatitis raises red flags, as GLP-1 agonists carry a theoretical (though rare) risk of pancreatitis recurrence. Patients with a history of retinal disease or diabetic retinopathy may proceed, but rapid glucose lowering in diabetics can temporarily worsen retinopathy, necessitating ophthalmology coordination.

Medication Interactions and Drug-Related Contraindications

Semaglutide works alongside most common medications but requires caution with insulin or sulfonylureas—agents that lower blood sugar independently. Combining semaglutide with these drugs increases hypoglycemia risk and often requires dose reduction of the other agent. Patients taking warfarin (a blood thinner) may experience altered drug levels as weight loss changes body composition and hepatic metabolism; warfarin dosing must be monitored closely during the first few weeks of semaglutide initiation. Certain antiarrhythmic medications and some cancer therapies have limited safety data alongside GLP-1 agonists, warranting provider review of the complete medication list.

Weight loss itself—a therapeutic goal—can trigger medication adjustments across multiple prescriptions. Antihypertensive doses often require reduction as weight decreases, since lower body weight naturally reduces medication half-life and clearance. Patients on psychiatric medications should discuss semaglutide with their prescriber, as appetite suppression and gastrointestinal changes can sometimes mask mood symptoms or create false impressions of medication efficacy. PlexusDx providers routinely cross-check medication lists and coordinate with patients' other doctors to prevent surprises.

How PlexusDx Assesses Your Semaglutide Candidacy

PlexusDx begins with a detailed intake form and telehealth consultation that covers medical history, current medications, family history of thyroid cancer, kidney function (via recent labs), and prior experience with weight loss or metabolic issues. Compounded semaglutide from licensed 503A pharmacies carries the same safety profile and contraindications as branded versions, so the same eligibility rules apply. PlexusDx providers do not require insurance approval, allowing faster assessment and initiation for qualified candidates. Once cleared, patients start compounded semaglutide injections at $189/mo (or $149/mo on the 6-month plan)—a flat rate that does not change as your dose increases—making predictable pricing accessible across all states.

The optional Precision Peptide Genetic Test ($298) provides additional insight into your individual peptide-pathway biology. By mapping variants in genes like GIPR rs1800437, PlexusDx identifies whether your weight challenge stems more from appetite dysregulation or metabolic inflexibility. This genetic data helps optimize which compound (semaglutide, tirzepatide, or a dual GLP-Squared formula) aligns best with your biology, improving long-term adherence and outcomes. Even without genetic testing, PlexusDx's clinical framework ensures that semaglutide candidates receive the right molecule at the right dose from day one.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

I have type 2 diabetes and take metformin. Can I take semaglutide?

Yes, many type 2 diabetics qualify for semaglutide, and the two drugs complement each other. If you also take insulin or sulfonylureas, your provider may need to reduce those doses to prevent low blood sugar. PlexusDx reviews your complete diabetes medication list during the eligibility assessment.

What if I have a family history of thyroid cancer?

A family history alone does not disqualify you, but a personal history of medullary thyroid carcinoma or MEN2 syndrome does. If you carry the MEN2 gene mutation, semaglutide is contraindicated due to animal studies showing thyroid tumors at high doses. Genetic counseling can clarify your specific risk.

Is compounded semaglutide from PlexusDx as safe as branded Wegovy?

PlexusDx sources compounded semaglutide from licensed 503A pharmacies under strict quality standards, and the active ingredient and safety profile are equivalent to branded versions. The main difference is cost and accessibility: PlexusDx charges a flat $189/month regardless of dose, serves all 50 states without insurance, and skips the branded-drug markup.

Can I take semaglutide if I am trying to get pregnant?

No, semaglutide is contraindicated in pregnancy and for at least two menstrual cycles before conception due to teratogenic risk. If you are planning pregnancy, discuss stopping semaglutide with your PlexusDx provider well in advance. The medication is also not recommended while breastfeeding.

How does the PlexusDx Precision Peptide Genetic Test help determine if semaglutide is right for me?

The Precision Peptide Genetic Test examines variants in 14 peptide pathways (49 peptides, 150+ insights) including GIPR genes. If you carry variants associated with lower GLP-1 pathway sensitivity, tirzepatide or PlexusDx's GLP-Squared dual compound may work better than semaglutide alone. This $99 test personalizes your treatment selection after your first month.

Related Reading

• Wegovy For Weight Loss 2
• Wegovy Weight Loss Pills
• Wegovy Vs Zepbound Weight Loss
• Wegovy Weight Loss

Pricing and availability current as of July 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.